Drug-eluting stent approved for peripheral arterial disease

November 16, 2012
Drug-eluting stent approved for peripheral arterial disease

(HealthDay)—The Zilver PTX Drug-Eluting Peripheral Stent has been approved by the U.S. Food and Drug Administration to treat peripheral arterial disease of the femoropopliteal artery.

The safety and effectiveness of the stent were evaluated in a clinical study of 479 people. After one year, 83 percent of narrowed arteries treated with the new stent were still open, compared with 33 percent in a control group, the FDA said.

The most common adverse reaction observed during the study was a re-narrowing of the affected artery, which required additional treatment to restore adequate blood flow.

Among those in whom the stent should not be used are women who are pregnant, breast-feeding, or who plan to become pregnant in the next five years, the FDA said.

Device maker Cook Inc., based in Bloomington, Ind., is required to conduct a five-year post-approval study involving some 900 people who have had the stent installed, the agency said.

Explore further: Glaucoma stent approved

More information: The U.S. National Heart Lung and Blood Institute has more about peripheral arterial disease.

Related Stories

Glaucoma stent approved

June 26, 2012

(HealthDay) -- An ocular stent that's designed to reduce inner-eye pressure among people with mild or moderate open-angle glaucoma has been approved by the U.S. Food and Drug Administration.

Recommended for you

Painkillers linked to heart failure: study

September 29, 2016

Widely used prescription and non-prescription painkillers are associated with an increased risk of hospital admission for heart failure, according to a study released Thursday.

Researchers mine Twitter for cardiovascular disease research

September 28, 2016

For years, marketers and other commercial data-miners have been using Twitter's vast database of "tweets" to gauge consumer attitudes and track events. Now medical researchers are getting in on the trend. Researchers from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.